Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Genetic Technologies Limited v. Merial L.L.C.
Case Number:
1:12-cv-00396
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
October 30, 2014
BMS, Sanofi Get Gene Patent Partially Invalidated In IP Suit
A Delaware federal judge invalidated part of a DNA technology patent Genetic Technologies Ltd. accused Bristol-Myers Squibb Co. and a Sanofi-Aventis SA unit of infringing because it merely described a natural law, dooming the claim under the U.S. Supreme Court's landmark Mayo v. Prometheus decision.
-
May 02, 2012
Prometheus Dooms DNA Analysis Patent, Merial Claims
A patent held by Genetic Technologies Ltd. on a method of using DNA in genetic analysis should be invalidated in light of the U.S. Supreme Court's recent Prometheus ruling, Sanofi-Aventis SA's animal health unit Merial Ltd. said in a re-examination request filed Monday.